Klasse, P.J.

Publications

Sort by

Co-Author Network

selected publications

Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site. Science immunology. 2024 Academic Article GET IT
Immunization with germ line-targeting SOSIP trimers elicits broadly neutralizing antibody precursors in infant macaques. Science immunology. 2024 Academic Article GET IT
The significance of antigen-antibody-binding avidity in clinical diagnosis. Critical reviews in clinical laboratory sciences. 2024 Review GET IT
Fusion peptide-directed antibodies: Humoral armor against HIV-1 infection. Science translational medicine. 2024 Review GET IT
Germline-targeting SOSIP trimer immunization elicits precursor CD4 binding-site targeting broadly neutralizing antibodies in infant macaques. 2023 GET IT
Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization. PLoS pathogens. 2023 Academic Article GET IT
Correction: HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. 2023 GET IT
Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization. Retrovirology. 2023 Academic Article GET IT
Times cited: 2
Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions. Cell reports. Medicine. 2023 Academic Article GET IT
Longitudinal antibody response kinetics following SARS-CoV-2 mRNA vaccination in pregnant and non-pregnant persons. American journal of obstetrics & gynecology MFM. 2022 Academic Article GET IT
Measurements of SARS-CoV-2 antibody dissociation rate constant by chaotrope-free biolayer interferometry in serum of COVID-19 convalescent patients. Biosensors & bioelectronics. 2022 Academic Article GET IT
The glycan hole area of HIV-1 envelope trimers contributes prominently to the induction of autologous neutralization. Journal of virology. 2021 Academic Article GET IT
TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. Clinical chemistry. 2021 Academic Article GET IT
Times cited: 11
Serologic response to mRNA COVID-19 vaccination in lymphoma patients. American journal of hematology. 2021 Letter GET IT
Times cited: 24
Antibodies from Rabbits Immunized with HIV-1 Clade B SOSIP Trimers Can Neutralize Multiple Clade B Viruses by Destabilizing the Envelope Glycoprotein. Journal of virology. 2021 Academic Article GET IT
Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva. Pathogens & immunity. 2021 Academic Article GET IT
Times cited: 83
Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health. The Journal of clinical endocrinology and metabolism. 2021 Academic Article GET IT
Times cited: 23
Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike. Cell reports. 2021 Academic Article GET IT
Times cited: 3
Association of Age With SARS-CoV-2 Antibody Response. JAMA network open. 2021 Academic Article GET IT
Times cited: 139
Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles. NPJ vaccines. 2021 Academic Article GET IT
Times cited: 31
Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients. Biosensors & bioelectronics. 2021 Academic Article GET IT
Times cited: 18
High-resolution mapping of the neutralizing and binding specificities of polyclonal sera post-HIV Env trimer vaccination. eLife. 2021 Academic Article GET IT
Times cited: 13
Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers. Journal of virology. 2020 Academic Article GET IT
Times cited: 14
COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds. Journal of virology. 2020 Information Resource GET IT
Times cited: 67
Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. PLoS pathogens. 2020 Academic Article GET IT
Times cited: 44
Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens. eLife. 2020 Academic Article GET IT
Times cited: 105
Seminal analyses of HIV-1 transmission. EBioMedicine. 2020 Article GET IT
Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?. Cell host & microbe. 2020 Information Resource GET IT
Times cited: 39
Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin. Journal of virology. 2020 Academic Article GET IT
Times cited: 26
SOS and IP Modifications Predominantly Affect the Yield but Not Other Properties of SOSIP.664 HIV-1 Env Glycoprotein Trimers. Journal of virology. 2019 Academic Article GET IT
Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes. Journal of virology. 2019 Academic Article GET IT
Times cited: 13
Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. Nature communications. 2019 Academic Article GET IT
Times cited: 131
Non-cognate ligands of Procrustean paratopes as potential vaccine components. EBioMedicine. 2019 Article GET IT
Times cited: 3
Optimizing the production and affinity purification of HIV-1 envelope glycoprotein SOSIP trimers from transiently transfected CHO cells. PloS one. 2019 Academic Article GET IT
Times cited: 16
Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes. Journal of virology. 2019 Academic Article GET IT
Times cited: 54
Collusion between neutralizing antibodies and other immune factions in the destruction of adenoviral vectors. Proceedings of the National Academy of Sciences of the United States of America. 2018 Article GET IT
Times cited: 3
Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers In Vitro. Journal of virology. 2018 Academic Article GET IT
Times cited: 32
Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination. Journal of virology. 2018 Academic Article GET IT
Times cited: 61
Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. PLoS pathogens. 2018 Academic Article GET IT
Times cited: 80
cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate. Biotechnology and bioengineering. 2017 Academic Article GET IT
Times cited: 59
High-Throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers. Journal of virology. 2017 Academic Article GET IT
Times cited: 21
Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. The Journal of experimental medicine. 2017 Academic Article GET IT
Times cited: 130
Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization. Cell reports. 2017 Academic Article GET IT
Times cited: 129
HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. PloS one. 2017 Academic Article GET IT
Times cited: 14
Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. Journal of virology. 2017 Academic Article GET IT
Times cited: 39
Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes. Journal of virology. 2017 Academic Article GET IT
Times cited: 25
A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure. Immunity. 2017 Academic Article GET IT
Times cited: 177
Recognition of HIV-inactivating peptide triazoles by the recombinant soluble Env trimer, BG505 SOSIP.664. Proteins. 2017 Academic Article GET IT
Times cited: 7
An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nature microbiology. 2016 Academic Article GET IT
Times cited: 120
HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike. Journal of virology. 2016 Academic Article GET IT
Times cited: 16
Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. PLoS pathogens. 2016 Academic Article GET IT
Times cited: 118
Quantitative Correlation between Infectivity and Gp120 Density on HIV-1 Virions Revealed by Optical Trapping Virometry. The Journal of biological chemistry. 2016 Academic Article GET IT
Times cited: 27
Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. Cell reports. 2016 Academic Article GET IT
Times cited: 210
How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses. Expert review of vaccines. 2016 Information Resource GET IT
Times cited: 47
Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. Cell. 2015 Academic Article GET IT
Times cited: 279
Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers. Virology. 2015 Academic Article GET IT
Times cited: 37
Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. Nature communications. 2015 Academic Article GET IT
Times cited: 74
Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens. Proceedings of the National Academy of Sciences of the United States of America. 2015 Academic Article GET IT
Times cited: 106
Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers. Journal of virology. 2015 Academic Article GET IT
Times cited: 73
Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity. Journal of virology. 2015 Academic Article GET IT
Times cited: 123
Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope Glycoprotein. AIDS research and human retroviruses. 2015 Academic Article GET IT
Times cited: 12
Predicting first traversal times for virions and nanoparticles in mucus with slowed diffusion. Biophysical journal. 2015 Academic Article GET IT
Times cited: 11
HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science (New York, N.Y.). 2015 Academic Article GET IT
Times cited: 424
Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. PLoS pathogens. 2015 Academic Article GET IT
Times cited: 86
What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?. Journal of virology. 2015 Academic Article GET IT
Times cited: 23
A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. Journal of virology. 2015 Academic Article GET IT
Times cited: 202
Molecular determinants of the ratio of inert to infectious virus particles. Progress in molecular biology and translational science. 2014 Article GET IT
Times cited: 29
Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives. Advances in biology. 2014 Academic Article GET IT
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature. 2014 Academic Article GET IT
Times cited: 370
Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. European journal of immunology. 2014 Academic Article GET IT
Times cited: 45
Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology. 2014 Academic Article GET IT
Times cited: 131
Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies. Retrovirology. 2014 Academic Article GET IT
Times cited: 45
Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application. The Journal of antimicrobial chemotherapy. 2013 Academic Article GET IT
Times cited: 13
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (New York, N.Y.). 2013 Academic Article GET IT
Times cited: 582
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (New York, N.Y.). 2013 Academic Article GET IT
Times cited: 715
Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proceedings of the National Academy of Sciences of the United States of America. 2013 Academic Article GET IT
Times cited: 154
A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS pathogens. 2013 Academic Article GET IT
Times cited: 740
Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. Journal of virology. 2013 Academic Article GET IT
Times cited: 77
Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. Journal of virology. 2013 Academic Article GET IT
Times cited: 68
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nature structural & molecular biology. 2013 Academic Article GET IT
Times cited: 288
Clinical adjuvant combinations stimulate potent B-cell responses in vitro by activating dermal dendritic cells. PloS one. 2013 Academic Article GET IT
Times cited: 14
Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants. Journal of virology. 2013 Academic Article GET IT
Times cited: 32
Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proceedings of the National Academy of Sciences of the United States of America. 2013 Academic Article GET IT
Times cited: 215
Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. Journal of virology. 2012 Academic Article GET IT
Times cited: 63
Potent induction of antibody-secreting B cells by human dermal-derived CD14+ dendritic cells triggered by dual TLR ligation. Journal of immunology (Baltimore, Md. : 1950). 2012 Academic Article GET IT
Times cited: 33
Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. The Journal of antimicrobial chemotherapy. 2012 Academic Article GET IT
Times cited: 54
Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220. The Journal of antimicrobial chemotherapy. 2012 Academic Article GET IT
Times cited: 29
HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells. Journal of immunology (Baltimore, Md. : 1950). 2012 Academic Article GET IT
Times cited: 25
Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines. Retrovirology. 2012 Information Resource GET IT
Times cited: 12
The molecular basis of HIV entry. Cellular microbiology. 2012 Information Resource GET IT
Times cited: 102
Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proceedings of the National Academy of Sciences of the United States of America. 2012 Academic Article GET IT
Times cited: 39
Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance. Virology. 2012 Academic Article GET IT
Times cited: 15
V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc. Virology. 2012 Academic Article GET IT
Times cited: 31
Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrobial agents and chemotherapy. 2012 Academic Article GET IT
Times cited: 61
Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. Journal of virology. 2011 Academic Article GET IT
Times cited: 38
SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses. PloS one. 2011 Academic Article GET IT
Times cited: 13
Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. Virology. 2011 Academic Article GET IT
Times cited: 18
Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. Journal of controlled release : official journal of the Controlled Release Society. 2011 Academic Article GET IT
Times cited: 49
Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice. AIDS research and human retroviruses. 2011 Academic Article GET IT
Times cited: 28
Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proceedings of the National Academy of Sciences of the United States of America. 2011 Academic Article GET IT
Times cited: 137
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proceedings of the National Academy of Sciences of the United States of America. 2011 Academic Article GET IT
Times cited: 228
Inhibition of p53 by adenovirus type 12 E1B-55K deregulates cell cycle control and sensitizes tumor cells to genotoxic agents. Journal of virology. 2011 Academic Article GET IT
Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. Journal of virology. 2011 Academic Article GET IT
Times cited: 54
How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?. AIDS research and human retroviruses. 2011 Information Resource GET IT
Times cited: 61
Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41. Virology. 2011 Academic Article GET IT
Times cited: 21
Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. The Journal of infectious diseases. 2010 Academic Article GET IT
Times cited: 126
IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS research and human retroviruses. 2010 Academic Article GET IT
Times cited: 97
Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers. Proceedings of the National Academy of Sciences of the United States of America. 2009 Academic Article GET IT
Times cited: 232
Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS pathogens. 2009 Academic Article GET IT
Times cited: 62
Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. Virology. 2009 Academic Article GET IT
Times cited: 45
Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology. 2009 Academic Article GET IT
Times cited: 37
Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proceedings of the National Academy of Sciences of the United States of America. 2009 Academic Article GET IT
Times cited: 86
Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249. Proceedings of the National Academy of Sciences of the United States of America. 2008 Academic Article GET IT
Times cited: 41
AIDS/HIV. A STEP into darkness or light?. Science (New York, N.Y.). 2008 Article GET IT
Times cited: 42
Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annual review of medicine. 2008 Information Resource GET IT
Times cited: 156
N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus. Virology. 2007 Academic Article GET IT
Times cited: 24
HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS pathogens. 2007 Academic Article GET IT
Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. Virology. 2007 Academic Article GET IT
Times cited: 72
Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology. 2007 Academic Article GET IT
Times cited: 46
Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes. Virology. 2007 Academic Article GET IT
Times cited: 31
A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology. 2006 Academic Article GET IT
Times cited: 85
Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1. Virology. 2006 Academic Article GET IT
Times cited: 39
Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex. Virology. 2006 Academic Article GET IT
Times cited: 19
HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. Journal of immunology (Baltimore, Md. : 1950). 2006 Academic Article GET IT
Times cited: 173
Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nature medicine. 2005 Academic Article GET IT
Times cited: 82
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature. 2005 Academic Article GET IT
Times cited: 270
The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology. 2005 Academic Article GET IT
Times cited: 61
Recombinant gp120, antibodies to the V3 region of gp120, and neural progenitor cells. The Journal of infectious diseases. 2005 Article GET IT
Times cited: 1
V3: HIV's switch-hitter. AIDS research and human retroviruses. 2005 Information Resource GET IT
Times cited: 237
Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses. Virology. 2004 Academic Article GET IT
Times cited: 47
Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. The Journal of experimental medicine. 2003 Academic Article GET IT
Times cited: 142
Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans. Journal of virology. 2003 Academic Article GET IT
Times cited: 89
Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. AIDS research and human retroviruses. 2003 Academic Article GET IT
Times cited: 47
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nature medicine. 2003 Academic Article GET IT
Times cited: 425
Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells. Journal of virology. 2003 Academic Article GET IT
Times cited: 56
Occupancy and mechanism in antibody-mediated neutralization of animal viruses. The Journal of general virology. 2002 Information Resource GET IT
Times cited: 215
Mechanisms of virus neutralization by antibody. Current topics in microbiology and immunology. 2001 Information Resource GET IT
Times cited: 46
CD4-Chemokine receptor hybrids in human immunodeficiency virus type 1 infection. Journal of virology. 1999 Academic Article GET IT
Times cited: 14
Mechanisms of enveloped virus entry into animal cells. Advanced drug delivery reviews. 1998 Academic Article GET IT
Differential regulation of CXCR4 and CCR5 endocytosis. Journal of cell science. 1998 Academic Article GET IT
Times cited: 120
Interactions among HIV gp120, CD4, and CXCR4: dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH- and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies. Virology. 1998 Academic Article GET IT
Times cited: 67
Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. Journal of virology. 1998 Academic Article GET IT
Times cited: 182
Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4. The Journal of cell biology. 1997 Academic Article GET IT
Times cited: 342
Promiscuous use of CC and CXC chemokine receptors in cell-to-cell fusion mediated by a human immunodeficiency virus type 2 envelope protein. Journal of virology. 1997 Academic Article GET IT
Times cited: 62
Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. The Journal of experimental medicine. 1997 Academic Article GET IT
Times cited: 110
Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. Journal of virology. 1997 Academic Article GET IT
Times cited: 161
Altered CD4 interactions of HIV type 1 LAI variants selected for the capacity to induce membrane fusion in the presence of a monoclonal antibody to domain 2 of CD4. AIDS research and human retroviruses. 1996 Academic Article GET IT
Times cited: 6
Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. Journal of virology. 1996 Academic Article GET IT
Times cited: 73
Antibody neutralization of HIV-1. Immunology today. 1996 Information Resource GET IT
Times cited: 88
HIV. Cyclophilins unfold the Gag?. Nature. 1993 Article GET IT
Times cited: 13
An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site. Virology. 1993 Academic Article GET IT
Times cited: 36
Soluble CD4 and CD4 immunoglobulin-selected HIV-1 variants: a phenotypic characterization. AIDS research and human retroviruses. 1993 Academic Article GET IT
Times cited: 20
Three-dimensional structure and antigenicity of transmembrane-protein peptides of the human immunodeficiency virus type 1. Effects of a neutralization-escape substitution. FEBS letters. 1993 Academic Article GET IT
Times cited: 4
A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. Journal of virology. 1992 Academic Article GET IT
Times cited: 128
Human and murine monoclonal antibodies directed against a conserved sequence from gp41 (aa583-599) of human immunodeficiency virus type 1. Research in virology. 1992 Academic Article GET IT
Times cited: 10
Thermodynamic and kinetic analysis of sCD4 binding to HIV-1 virions and of gp120 dissociation. AIDS research and human retroviruses. 1992 Academic Article GET IT
Times cited: 43
Kinetics of the HIV-CD4 interactions and virus-cell fusion. AIDS (London, England). 1992 Editorial Article GET IT
Times cited: 7
Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro. Virology. 1991 Academic Article GET IT
Times cited: 42
A cluster of continuous antigenic structures in the transmembrane protein of HIV-1: individual patterns of reactivity in human sera. Molecular immunology. 1991 Academic Article GET IT
Times cited: 6
HIV-1 neutralization directed to epitopes other than linear V3 determinants. AIDS (London, England). 1991 Information Resource GET IT
Times cited: 14
Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp41, defined by a human monoclonal antibody. Journal of virology. 1990 Academic Article GET IT
Times cited: 18
The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope. Journal of virology. 1990 Academic Article GET IT
Times cited: 70
Antibodies to a putative HIV gp41 immunosuppressive peptide, pHIVIS (583-599), do not correlate significantly with outcome in HIV infection. AIDS (London, England). 1990 Academic Article GET IT
Times cited: 16
Cross-reactivity with SIVmac in east African HIV-1-positive sera: evidence against double infection with HIV-1 and a SIVmac/HIV-2-like virus. Intervirology. 1990 Academic Article GET IT
Times cited: 1
Differential IgG subclass responses to epitopes in transmembrane protein of HIV-1. Viral immunology. 1990 Academic Article GET IT
Times cited: 7
An aberrant subclass pattern of HIV-specific immunoglobulin G in sera from haemophiliacs. AIDS (London, England). 1988 Academic Article GET IT
Times cited: 4
Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects. Proceedings of the National Academy of Sciences of the United States of America. 1988 Academic Article GET IT
Times cited: 107
Quantification of immunoglobulin on electrophoretic immunoblot strips as a tool for human immunodeficiency virus serodiagnosis. Journal of clinical microbiology. 1988 Academic Article GET IT
Times cited: 8
Specificities and sensitivities of three systems for determination of antibodies to human immunodeficiency virus by electrophoretic immunoblotting. Journal of clinical microbiology. 1988 Academic Article GET IT
Times cited: 10
Patterns of antibodies to human immunodeficiency virus proteins in different subclasses of IgG. The Journal of infectious diseases. 1987 Academic Article GET IT
Times cited: 24
Anti-STLV-IIImac reactivity in HIV seropositive individuals in Sweden. Lancet (London, England). 1986 Article GET IT
Times cited: 3

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Neutralization of primary HIV-1 viruses awarded by National Institute of Allergy & Infectious Diseases Co-Investigator 2023 - 2028
missing activity Co-Investigator 2019 - 2024

Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies awarded by National Institute of Allergy & Infectious Diseases Co-Principal Investigator 2020 - 2025
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies awarded by National Institute of Allergy & Infectious Diseases Co-Principal Investigator 2021 - 2022

more ...

less ...

Background

education and training

Ph.D., University of Lund (Sweden) 1992
M.D., University of Lund Faculty of Medicine (Sweden) 1986

Contact

full name

P.J. Klasse

primary email

pek2003@med.cornell.edu

VIVO Weill Cornell Medical College

P.J. Klasse Professor of Research in Microbiology and Immunology

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email